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ABsTRAcT: Seven- to 8-day-old Arc/Swiss mice were infected with 100,000-120,000 Cryptosporidium  parvum oocysts. At 8 
days postinfection  (PI) the jejunum, ileum, cecum, colon, and rectum  were removed. Using a simple extraction  procedure  and 
purification  by Ficoll gradient  centrifugation,  we rountinely  obtained  between  3-6 million and up to 15 million purified  oocysts 
per mouse. For in vitro cultivation, purified  oocysts were pretreated  in a low pH (2.5-3) 0.5% trypsin solution for 20 min, 
resuspended  in supplemented  RPMI-1640 containing  glucose 0.1 g (5.55 mM), sodium bicarbonate  0.3 g, bovine bile 0.02 g, 
folic acid 25  tg, 4-aminobenzoic  acid 100 Mg,  calcium pantothenate  50 Mg,  ascorbic  acid 875 gg, penicillin G 10,000 U and 
streptomycin  0.01 g per 100 ml, and 1%  fetal  bovine serum  (pH 7.4 before  filtration),  and used to inoculate  confluent  monolayers 
of the human adenocarcinoma  cell line HCT-8. Incubation  was in a candle  jar at 37 C. We tested numerous  supplements  to 
RPMI-1640, different  pHs, and atmospheric  conditions  and found  the parameters  described  above produced  the greatest  parasite 
numbers  in vitro. We obtained  significantly  superior  growth  of C. parvum  grown  in HCT-8 cells using the conditions  described 
above than in culture  conditions described  previously. 
Cryptosporidium is  a  protozoan  parasite  with  a worldwide 
distribution.  Cryptosporidium parvum is the species  found  in- 
fecting a range of domestic  and wild animals, and humans (Case- 
more,  1990;  Fayer et  al.,  1990;  O'Donoghue,  1995)  between 
which cross-transmission  can occur (reviewed by O'Donoghue, 
1995).  The parasite primarily invades  the epithelium  of the 
gastrointestinal  tract  of  infected  hosts  causing  asymptomatic 
infections  or an acute or chronic cholera-like  diarrheal disease, 
which can be life-threatening or cause failure to thrive in infants, 
children,  and immunocompromised  individuals  (Isaacs et al., 
1985; Current, 1989; Guarino et al.,  1995). The serious nature 
of cryptosporidiosis  in high risk groups is compounded  by the 
lack  of  curative  treatment  strategies.  In this  respect,  a major 
limiting  factor  has  been  the  lack  of  a  cultivation  system  for 
biochemical  studies  and  for the  systematic  assessment  of  po- 
tential  anticryptosporidial  chemotherapeutic  agents. 
An important  prerequisite for the establishment  of a suitable 
cultivation  system  for  C. parvum  is  a reliable  and  easily  ob- 
tainable  source of oocysts,  a simple  oocyst  purification proce- 
dure, and identification  of optimal  conditions  for growth. Al- 
though  many  studies  have  reported the  in vitro  development 
of  C. parvum in various  cell lines,  most  of these  studies  have 
found  that, despite  some  development  of  C. parvum,  the per- 
centage of cells infected  is low. The work of Upton,  Tilley,  and 
Brillhart (1994a,  1994b,  1995) and Upton,  Tilley,  Nesterenko, 
and Brillhart (1994) has identified a number of important growth 
additives,  culture conditions,  and a cell line that has been shown 
to greatly enhance  growth of C. parvum in vitro.  We have  ex- 
amined  a number  of these  variables  and have  optimized  con- 
ditions  in  our laboratory  that  produce  superior growth  of  C. 
parvum  in  vitro.  In addition,  we  report a simple  method  for 
obtaining large quantities of purified oocysts from mice suitable 
for in vitro cultivation  and for molecular and biochemical  stud- 
ies. 
MATERIALS  AND  METHODS 
Cryptosporidium  isolates 
The C. parvum  isolate used for the majority  of in vivo and in vitro 
manipulations  in this study was originally  obtained  from a calf in Mil- 
licent, South Australia  in  1993 and has subsequently  been passaged 
through  mice in our laboratory.  This C. parvum  isolate was designated 
Cl. Cryptosporidium  parvum  isolates  from  humans  were  obtained  from 
individuals  in Western  Australia  and used to inoculate  mice (Table  I) 
and 1 isolate (H2) used for in vitro cultivation. The calf isolate and 
several  human isolates have been previously  characterized  by Morgan 
et al. (1995). 
Infection  of mice and collection  of oocysts 
We have modified the method described  by Current  (1990) for re- 
covering  oocysts  from mice. Seven-  to 8-day-old  ARC/Swiss  mice (An- 
imal Resources  Centre,  Murdoch,  Western  Australia)  were inoculated 
with 100,000-120,000 oocysts per os using a plastic  tube (diameter  0.7 
mm) attached  to a 1-ml syringe.  Mice began shedding  oocysts on day 
4 postinfection  (PI). Fecal samples were collected per rectum  on days 
6 and 7 PI and placed into dH20O  (distilled  water)  (  0.25 ml/mouse) 
containing  0.02%  Tween-20 (BDH, Poole, England)  and stored  at 4 C. 
On day 8 PI, mice were killed (CO2  exposure)  and the jejunum,  ileum, 
cecum, colon, and rectum  removed, placed in dH20/0.02% Tween-20 
(approximately  4 ml/mouse), and dissected  into smaller  segments.  In- 
testinal and fecal material was pooled and Sputasol (0.005 g/ml of 
suspension;  Oxoid, Hampshire,  England)  added before the suspension 
was thoroughly  homogenized  at 4 C. The homogenate  was left at RT 
(room temperature)  for 90-120 min on a rotary mixer before centri- 
fuging  at 2,000 g for 10 min. The suspension  was washed twice with 
cold dH20/0.02% Tween-20 by centrifuging  at 2,000 g for 8 min. An 
ether extraction  was performed  by resuspending  the oocyst-containing 
pellet first  with dH20/0.02%  Tween-20,  adding  ether  (2 ml of ether  per 
8 ml of suspension)  and mixing vigorously  (20-30 sec) before centri- 
fuging  at 2,000 g for 8 min. The supernatant  layers  were removed,  and 
the pellet  was  washed  twice  in cold dH20 as described  above.  Additional 
oocysts  were  recovered  by remixing  the supernatant  layers  following  the 
ether  extraction  and  recentrifuging  as described  above  to pellet  and  wash 
oocysts. Oocysts were resuspended  in cold sterile  PBS (phosphate-buf- 
fered saline)  and stored  at 4 C until further  purification. 
Purification  of oocysts collected  from  mice 
Oocysts were further  purified  using a modification of the method 
described  by Lumb et al. (1988). Modifications  included reduction  of 
the number  of Ficoll gradients  from 6 to 2 and changing  the centrifu- 
gation speed and time. Gradients  were formed  by layering  2.5 ml of a 
0.5%  and 1.0%  Ficoll 400 (Pharmacia,  Uppsala, Sweden)  solution pre- 
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TABLE  I.  Results of mice inoculated  with different  human (and calf) isolates of C. parvum. 
Isolate  Sex and age  Age and strain  No. of mice  Oocyst  Gutl 
code  of patient*  of mouse  infected  dose/mouse  Fecest  (oocysts/mouse) 
PAH  F, 2 yr  7-day ARC/Swiss  5  20,000  -  - 
PAH  F, 2 yr  7-day BALB/c  3  20,000  -  - 
PP  M, 3 yr  6-day BALB/c  5  20,000  -  - 
KW  F,  1 yr  6-day BALB/c  7  50,000  -  - 
084  NA  6-day BALB/c  5  100,000  -  - 
GM  M, 43 yr  6-day BALB/c  5  10,000  -  - 
H5  M, 7 yr  6-day BALB/c  5  100,000  +  + 
CNA  M, 1 yr  8-day ARC/Swiss  8  80,000  +-2+  5,000 
H11  NA  8-day ARC/Swiss  8  100,000  -  - 
H10  F, 7 yr  8-day ARC/Swiss  8  100,000  -  - 
H6  M, 3 yr  8-day ARC/Swiss  8  100,000  -  - 
H2  NA, 6 yr  7-day ARC/Swiss  30  100,000  +-4+  2-6 million 
H4  M, 8 yr  7-day ARC/Swiss  8  100,000  -  - 
H1  M, 2 yr  7-day ARC/Swiss  4  100,000  -  - 
H1  M, 2 yr  7-day ARC/Swiss  4  1,000,000  -  - 
Cl  Calf  7-day ARC/Swiss  > 100  100,000  +-4+  3-6 million 
* NA = information  not available. 
t Feces  examined  by preparing  direct  fecal  smears  and  staining  with  safranin. 
$  Gut  examined  by  preparing  smears  from  cecal  contents  and  staining  with  safranin.  Oocysts  quantitated  after  purification  as  described  in the  Materials  and  Methods. 
pared  in PBS containing 16%  sodium diatrizoate  (ICN, Aurora,  Ohio) 
into a 10-ml centrifuge  tube starting  with the 1.0%  Ficoll layer at the 
bottom. Two to 4 ml of oocyst suspension  was layered  onto the top of 
a cold Ficoll  gradient  (4 C) and tubes  centrifuged  (swinging  bucket  rotor) 
for 15 min at 1,000 g at RT. Oocysts  were  collected  from  the PBS/0.5% 
Ficoll interphase  and washed  twice with cold dH20O  as described  above. 
Additional oocysts were also recovered  following Ficoll gradient  cen- 
trifugation  by resuspending  pellets in PBS and recentrifuging  on fresh 
gradients  and collecting oocysts as described  above. Purified  oocysts 
were  resuspended  in cold sterile  PBS and 15 Ml  of an antibiotic  solution 
(gentamycin  5.0 mg/ml, lincomycin 4 mg/ml, ampicillin 10 mg/ml) 
added per ml of resuspended  oocysts before storage  at 4 C. 
In  vitro  cultivation 
Excystation  of oocysts  and culture  medium: Excystation  was carried 
out by exposing  0. 1-1-ml aliquots  of purified  oocysts to 9 ml of freshly 
prepared  excystation medium consisting of filter-sterilized  (0.22 4m 
filter)  dH20 (pH 2.5-3) containing  0.5%  trypsin  (1:250;  Difco, Detroit, 
Michigan)  and incubating  at 37 C for 20 min, with mixing every 4-6 
min. The excystation  suspension  was centrifuged  at 1,500 g for 4 min 
at RT, oocysts resuspended  in RPMI-1640  (Sigma,  St. Louis, Missouri) 
basal medium (RPMI-1640bm)  containing  sodium bicarbonate  0.3 g, 
bovine bile 0.02 g (Sigma),  penicillin G 10,000 U, and streptomycin 
0.01 g per 100 ml (adjusted  to pH 7.4 before  filtration). 
Preparation  and infection  of host cells: We evaluated  the cell lines 
MDCK, Caco-2, human  fibroblasts  (HF, Health Laboratories  of West- 
ern Australia),  HT-29, a colon cancer  cell line (LIM1215;  Ludwig  In- 
stitute  for Cancer  Research,  Victoria,  Australia;  Whitehead  et al., 1985), 
and HCT-8 (ATCC;  CCL244).  In preliminary  testing,  we found  that  the 
human ileocecal adenocarcinoma  cell line HCT-8 supported  the best 
growth  of C.  parvum  and was subsequently  used for routine  cultivation. 
HCT-8  cells  were  maintained  in 25-cm2  tissue  culture  flasks  in RPMI- 
1640 supplemented  with 1%  fetal  bovine serum  (FBS;  Gibco,  Auckland, 
New Zealand),  antibiotics  (as  above),  and  sodium  bicarbonate  (as  above) 
at 37 C in a 5%  CO2  incubator.  For subculture,  HCT-8 cells were  grown 
in RPMI-1640 containing  10%  FBS. HCT-8 cultures  that had recently 
reached  confluent  monolayers  grown  in 25-cm2  flasks  or 24 well plates 
were inoculated with C. parvum by removing existing medium and 
replacing  it with  RPMI-1640bm  containing  pretreated  oocysts  (see  above) 
and incubating  at 37 C in a candle  jar for between  80 and 90 min. The 
medium was then removed and replaced  with RPMI-1640 containing 
different  supplements  and incubated  for 72-120 hr at 37 C under  dif- 
ferent  atmospheres  (see below). We routinely  used an oocyst inoculum 
of between  2,000 and 5,000 oocysts/cm2  of culture  area. 
Growth  supplements  and culture  conditions: The following  supple- 
ments were added to RPMI-1640 and evaluated for their effects on 
cryptosporidial  growth:  0.01, 0.015, 0.02, 0.03, 0.04, 0.05, 0.06, and 
0.08 g/100 ml bovine bile;  0.1, 0.25, 0.3, and  0.6 g/100 ml biosate  (BBL, 
Cockeysville,  Maryland);  0.3 g/100 ml lactalbumin  (Sigma);  0.3 g/100 
ml yeast extract  (BBL);  0.3 g/100 ml trypticase  (BBL);  0.3 g/100 ml 
tryptone  (Oxoid);  0.3 g/100 ml tryptone  (Difco);  0.3 g/100 ml peptone 
(Sigma);  0.3 g/100 ml Trichomonas  medium (Oxoid);  0.02 g/100 ml 
sodium  taurocholate  (BDH);  0.1, 0.25, 0.3, 0.4, and  0.5 g/100 ml sodium 
bicarbonate;  0.24 and 0.1 U/ml insulin; 1 and 2 mM sodium  pyruvate; 
50 and 100  MM  mercaptoethanol;  0.5 and 1 mM cysteine;  0.01 and 0.02 
g/100 ml ascorbic  acid (Sigma);  nonessential  amino acids (Flow, Mc- 
Lean, Virginia);  5.55, 6.25,  12.5, 25, and 50 mM glucose; 1%  Ficoll 
400;  1 mM glutathione; 15 and 20 mM Hepes; 1%  hypoxanthine- 
thymine medium supplement  (Sigma);  1, 2, 5, and 10%  FBS;  2, 5, and 
10% new born calf serum (CSL, Parkville, Australia),  and omitting 
serum.  The complete  medium  was as described  by Upton et al. (1995), 
in addition  to the vitamin mixture:  100 
/g/100 
ml folic acid (ICN),  400 
gg/100 ml 4-aminobenzoic  acid (ICN), 200 gg/100 ml calcium panto- 
thenate  (ICN), 3,500 ,g/100  ml ascorbic  acid (Sigma),  added  at 20, 25, 
50, and 100%  original  concentrations.  Many  of these supplements  were 
also tested in combination  and under  different  atmospheric  conditions 
including  5%  CO2,  anaerobic,  candle  jar, and microaerophilic.  We have 
also assessed media adjusted  to the pH values (before  filtration)  7.15, 
7.25, 7.35, 7.4, 7.55, and 7.75. 
Microscopy  and examination  of cultures 
We used standard  light  microscopy  to examine  cultures.  An Olympus 
IM or Olympus IMT-2 inverted microsope (the former fitted with a 
heating  chamber)  were set-up  with a blue filter  and raised  condenser  to 
provide optimal viewing conditions. Parasitic  stages were easily iden- 
tified using this system and cultures  were examined daily at magnifi- 
cations ranging  from x 150 to x 600. 
Quantitation  of growth 
A semiquantitative  method was developed to assess growth of C. 
parvum.  Cell monolayers  grown  in 24-well plates  were inoculated  with 
5,000 oocysts/well and after incubation  in RPMI-1640bm for 80-90 
min, replaced  with different  medium formulations  and incubated  for 
72 hr. Growth was quantified  in duplicate  wells after wells had been 
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FIGURE  1.  Light  photomicrographs  of developmental  stages  of C parvum  in HCT-8  cells  in vitro  48 hr after  infection.  Medium  used  was 
optimized  RPMI-1640  (see  text)  and  incubation  was  in a candle  jar.  Magnification:  (a) x 200;  (b) x 400. 
washed  2 times  in PBS,  filled  with  1 ml Hank's  balanced  salt  solutiuon, 
and  scoring  the  absence  or presence  of 1 or more  endogenous  stages  in 
5 random  fields,  6 times  per  well  at x 600 magnification,  i.e., 30 fields 
per  well,  60 fields  per  growth  condition  tested.  Growth  data  were  an- 
alyzed  using  the  nonparametric  Mann-Whitney  U-test. 
RESULTS 
Mouse  model  and oocyst purification 
Using our mouse model and a Ficoll gradient purification 
method for obtaining  oocysts we routinely  obtained  between  3- 
5( 
c  o 
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FIGuRE  2.  Comparison  of growth  of C. parvum  after 72 hr: (a) op- 
timized  RPMI-1640  (see text)  incubated  in a candle  jar; and (b) as 
described  by Upton  et al. (1995) using  5%  CO2  (*P <  0.001).  Growth 
was  assessed  by  scoring  the  absence  or  presence  of 1  or  more  endogenous 
stages  in 5 fields,  6 times  in each  of 2 wells  using  a light  microscope  at 
x 600 magnification. 
6 million and up to 15 million oocysts/mouse. Oocyst recovery 
rates from mouse fecal/intestinal  homogenates  were found to 
be between  65 and 85%.  Phase-contrast  examination  of purified 
oocysts revealed clean preparations  with minimal or no con- 
tamination with debris, bacteria,  or yeast. 
We have infected neonatal mice (6-8 days) with oocysts iso- 
lated from 15 different  human  fecal  samples  (Table  I). We found 
that oocysts from 1 of these isolates  (H2) produced  a high  oocyst 
excretion  rate  comparable  to that obtained  from the calf isolate 
(Cl  1)  used  in this study,  whereas  the remaining  samples  produced 
no or low oocyst excretion  rates in mice (Table I). 
In  vitro  cultivation 
Using RPMI-1640bm, we tested 6 cell lines (MDCK, Caco- 
2, HF, HT-29, LIM1215,  and HCT-8)  and  found  that  the human 
cecal adenocarcinoma  cell line HCT-8 produced the highest 
parasite  numbers  in vitro. We observed that confluent  HCT-8 
monolayers more than 2 days old, and monolayers with less 
than 100%  confluency  did not produce  comparable  numbers  of 
endogenous stages to those obtained with recently confluent 
monolayers. 
Many of the media supplements  described  above were used 
alone, in combination, or both, and although not all combi- 
nations at different  atmospheres  and pH were tested, we have 
formulated  a medium and incubation conditions that provide 
optimal growth. The optimum medium composition and in- 
cubation  conditions  were  as follows:  RPMI-  1640 supplemented 
with sodium bicarbonate  0.3 g, bovine bile 0.02 g, glucose 0.1 
g, folic acid 25 ug, 4-aminobenzoic acid 100 ug, calcium pan- 
tothenate  50  tg,  ascorbic  acid 875 ug, per 100 ml, pH 7.4 (before 
filtration), 1%  FBS, and incubate in candle jar at 37 C, with 
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medium changes  every 48 hr (Fig. 1).  This formulation  replaced 
RPMI-1640bm for resuspending  oocysts after pretreatment  in 
trypsin  and was used to infect cell monolayers  directly. 
We have compared growth of C  parvum  in our optimized 
medium and in that described  by Upton et al. (1995) grown  in 
a candle  jar and in a 5%  CO2 incubator.  We observed superior 
growth  of C.  parvum  in our optimized medium with incubation 
in a candle  jar compared  to growth  in medium and conditions 
described  by Upton et al. (1995) (Fig. 2) and found that peak 
numbers  of endogenous  stages  occurred  between 48 and 72 hr. 
Although  growth  in our  optimized  medium  was not significantly 
different  in cultures  incubated  in a candle  jar or in 5%  CO2,  we 
consistently observed better growth in cultures incubated in 
candle  jars. Incubating  cultures  in anaerobic  or microaerophilic 
atmospheres  resulted  in poor growth  of C parvum. 
DISCUSSION 
In this study,  best oocyst yields were  obtained  from  mice aged 
between 7 and 8 days at the time of infection and by collecting 
fecal  samples  before  harvesting  oocysts  from  the gastrointestinal 
tract  on day 8 PI. Current  (1990) also recommended  harvesting 
oocysts from the gut of infected mice on day 8 PI, and a study 
by Sinski et al. (1992) using mice infected at 3-6 days of age 
produced  peak intestinal oocyst numbers  8 days PI. 
Experimentally  infected  neonatal  mice have been used  to study 
the life cycle, development,  and infectivity  of C parvum  (Sher- 
wood et al., 1982; Current  and Reese, 1986;  Ernest  et al., 1986; 
Scaglia et al., 1991; Novak and Sterling, 1991; Sinski et al., 
1992), to assess oocyst viability (Sherwood  et al., 1982; Fayer 
et al., 1991), to test drugs against the parasite  (Tzipori et al., 
1982;  Angus  et al., 1984; Blagburn  et al., 1991; Fayer  and Ellis, 
1993; Rohlman et al., 1993), and in immunological  studies of 
cryptosporidiosis  (Moon  et al., 1988;  Harp  and Whitmire,  1991). 
Although Current  (1990) described a technique for isolating 
oocysts from the gut of infected mice, this is the first  study that 
describes  a technique  in which oocysts have been obtained  from 
mice, further purified using a simple procedure, and subse- 
quently  used for the reproducible  establishment  of in vitro cul- 
tures. 
Although  the number  of oocysts generated  using experimen- 
tally infected mice in the present study (3-15 million oocysts/ 
mouse; after purification)  is less than the number  usually shed 
by infected neonatal  calves (1-10 million oocysts/g of feces for 
1 wk; Angus, 1990), it provides ample material for in vitro 
cultivation  and small-scale  molecular  (Morgan  et al., 1995) and 
biochemical studies. In addition, the smaller oocyst yields ob- 
tainable  using  mice are  compensated  for  by the ease in handling, 
maintaining,  and processing  material  from mice  infected  with 
C. parvum compared  to calves  and other large animals. 
The  oocyst  purification  method  is simple  to perform, inex- 
pensive,  and was found to be very reliable. The Ficoll gradients 
can be prepared in advance  and stored at 4 C for up to  6 mo 
without  any loss in performance.  Oocyst preparations are very 
clean  and  when  used  for in  vitro  cultivation  do  not  result in 
bacterial or yeast contamination.  Purified oocysts stored in PBS 
were successfully used to infect mice and susceptible cell mono- 
layers after 6 mo storage. We have noticed, however, that oocyst 
storage results in a gradual decline  in the efficiency of oocysts 
to produce endogenous  stages in vitro compared to fresh oocysts 
and, therefore,  rountinely  use oocysts less than 6 mo old for 
cultivation. Storage  in PBS also enables oocysts to be used for 
in vivo and in vitro infections,  as well as DNA and biochemical 
procedures  directly  without the necessary  wash procedures  re- 
quired  when working  with oocysts stored in dichromate. 
The variation  in infectivity of isolates of C parvum  in mice 
is likely to be a reflection  of the differences  in host specificity 
of the parasite.  This is supported  by the results  of genetic  char- 
acterization,  which revealed  that the human C parvum  isolate 
H2, which produced high oocyst excretion rates in mice was 
more closely related  to calf isolates (including  Cl) than to other 
closely related  human isolates of C parvum  (HI1,  H4, H5, H 6, 
H10, H 11; Morgan  et al., 1995) that produced  low, or no, in- 
fections in mice. Other cross-transmission  studies have also 
revealed  differences  and similarities  in infectivity  and virulence 
of calf and human  isolates of C parvum  in different  hosts (Cur- 
rent et al., 1983; Current  and Reese, 1986; Pozio et al., 1992). 
However, this is the first  study to compare  the infectivity  of C 
parvum in mice using genetically  characterized  isolates and to 
show that genetically  related  isolates behave similarly  in vivo. 
These findings also support our initial suggestion  (Morgan  et 
al., 1995) that different  isolates of C parvum  are likely to vary 
in their zoonotic potential. 
We used oocysts that had been exposed to a simple pretreat- 
ment step and resuspended  in media containing  bile to infect 
cell monolayers. This procedure  has 3 advantages  over using 
sporozoites  to infect  cells:  (1) it is simple  to perform  and  requires 
only 1 centrifugation  step;  (2) sporozoites  have not been exposed 
to undue stress such as filtration  and centrifugation  associated 
with sporozoite  purification  procedures;  and (3) once sporozo- 
ites are released  from the oocyst they are in immediate contact 
with host cells.  Upton, Tilley,  and Brillhart  (1994a, 1994b, 1995) 
and Upton, Tilley, Nesterenko,  and Brillhart  (1994) used a Clo- 
rox pretreatment  of oocysts before infecting  cells for the same 
reason as discussed above; however, their procedure  requires 
additional centrifugation  steps to remove the Clorox from the 
oocysts before infecting  cells. 
We found that FBS concentrations  above 2%  were  inhibitory 
and resulted  in a reduced  growth  of C parvum  with increasing 
concentrations,  in addition to causing  host cell overgrowth  and 
making visualization of the endogenous stages difficult.  Inter- 
estingly, omission of serum from the medium usually resulted 
in an increase in parasite  numbers compared  to cultures  with 
serum, even after 72 hr, which is in contrast  to the findings  of 
Gut et al. (1991). However,  the omission of serum  from  cultures 
also resulted  in a slight  deterioration  of the host cell monolayer 
and, therefore,  to reduce this effect, 1%  FBS was added to the 
optimum  medium  formulation. 
The  removal  of oocysts  80-90  min  after infecting  cells was 
not necessary and does not inhibit development  of C. parvum, 
which  is in contrast to the findings of Eggleston et al. (1994). 
Under  our conditions,  the pH of the medium  usually remains 
alkaline even after 72 hr, unlike the medium described by Upton 
et al.  (1995),  which  changed  to an acidic  pH  after 24  hr, due 
likely to the high serum (10%) and glucose (11 g/L) concentra- 
tion. 
In our growth studies, we used between  2,000  and 5,000  oo- 
cysts/cm2 of culture area, which is far fewer oocysts  (or sporo- 
zoites)  than described in other studies (on the order of  10,000- 
1,000,000  oocyst/cm2;  Current and Haynes,  1984; Flanigan et 
This content downloaded by the authorized user from 192.168.52.63 on Wed, 28 Nov 2012 20:06:32 PM
All use subject to JSTOR Terms and ConditionsMELONI  AND  THOMPSON-C.  PARVUM:  IN  VIVO  AND  IN  VITRO  761 
al., 1991; Rasmussen  et al., 1993;  Eggleston  et al., 1994;  Upton, 
Tilley, and Brillhart,  1994a, 1994b, 1995; Upton, Tilley, Nes- 
terenko, and Brillhart, 1994; Woods et al., 1995), and we still 
achieved high cell infection rates. We consistently  obtained  in- 
fection rates of between 30 and 60% after 2-4  days growth. 
Higher infection rates were achieved with higher  oocyst doses. 
Growth  of a human  isolate  (H2) of C.  parvum  produced  a similar 
level of infection  and development  as the calf isolate, Cl. It was 
observed, however, that optimal conditions for growth of C. 
parvum  in HCT-8 cells were  not the ideal conditions  for  growing 
the parasite in other cell lines. Therefore,  it is essential that 
optimal  culture  conditions  be determined  for  growing  C.  parvum 
in different  cell types. 
Although no attempt was made to quantify  the different  en- 
dogenous stages present during in vitro growth, we identified 
type 1 meronts, macrogamonts,  microgamonts,  and immature 
stages, and have also observed merozoites  being released  from 
meronts and merozoites infecting cells. We did not identify 
oocysts,  a result  consistent  with the finding  of Upton et al. (1995) 
who reported limited oocyst production in HCT-8 cells. We 
would like to point out 3 observations  of interest. One is that 
although numerous macrogamonts  were produced  during cul- 
tivation, we never observed 4 merozoites being released  from 
a meront. This is surprising  because it is known that the 4 
merozoites contained in type 2 meronts give rise to macroga- 
monts (and microgamonts)  (Fayer  et al., 1990). Secondly,  once 
merozoites were released from the meront they infected cells 
very quickly, usually within 30 sec, but often after only a few 
seconds.  The penetration  of the merozoite  into the host cell was 
very rapid and did not appear  to involve any prior  attachment 
or adhesion  to the cell. In addition,  if a merozoite  failed  to infect 
a cell within 1 min, it invariably  did not infect a cell thereafter. 
Finally,  we consistently  observed  merozoites  being  released  from 
meronts shortly  after medium changes  (1-15 min), and we be- 
lieve this to be a result  of the sudden  rise in pH that occurs  after 
adding fresh medium. 
In this study, we described a mouse model that is easy to 
handle and maintain and, combined with a purification  pro- 
cedure, provides a relatively simple method for the establish- 
ment of the parasite  in most laboratories.  In addition, we have 
simplified  and optimized  in vitro cultivation  methods.  This was 
achieved  by performing  a 1-step  excystation  procedure  for  treat- 
ing oocysts  prior  to inoculating  cells,  using  supplemented  RPMI- 
1640, reducing  the serum  concentration,  and  incubating  cultures 
in a candle  jar. Until an in vitro cultivation  method  is developed 
that allows for the production  of large  numbers  of oocysts and 
continuous  culture  of C.  parvum,  the procedures  outlined  in this 
study  will  be  of great benefit  to  current and  future reseachers 
working on this intriguing parasite. 
ACKNOWLEDGMENTS 
The  authors  thank  Russ  Hobbs  for statistical  advice,  Peter 
O'Donoghue,  University  of  Queensland,  Queensland,  Martin 
French,  Royal  Perth  Hospital,  Western  Australia,  N.  Hung, 
Princess  Margaret  Hospital,  Western  Australia  and  Brian 
McKenzie,  State  Health  Laboratories,  Western  Australia  for 
providing fecal samples containing  C. parvum. This project was 
funded by the Commonwealth  AIDS Research Council through 
a grant to B.P.M. 
LITERATURE  CITED 
ANGus,  K. W.  1990. Cryptosporidiosis  in ruminants.  In Cryptospor- 
idiosis  of man  and  animals,  J. P. Dubey,  C.  A. Speer,  and  R. Fayer 
(eds.).  CRC  Press,  Boca  Raton,  Florida,  p. 83-104. 
, G. HUTcmHsoN,  I. CAMPBELL,  AN  D. R. SNODORASS.  1984. 
Prophylactic  effects  of anticoccidial  drugs  in experimental  murine 
cryptosporidiosis.  Veterinary  Record  114:  166-168. 
BLAGBURN,  B. L.,  C.  A. SuNDERMANN,  D. S.  LINDsAY, J. E.  HAiLAND 
R. R. TIDWELL.  1991.  Inhibition  of Cryptosporidium  parvum  in 
neonatal  Hsd:  (ICR)BR  Swiss  mice  by polyether  ionophores  and 
aromatic  amidines.  Antimicrobial  Agents  and  Chemotherapy  35: 
1520-1523. 
CASEMORE,  D. P.  1990. Epidemiological  aspects  of human  cryptos- 
poridiosis.  Epidemiology  and Infection  104: 1-28. 
CuRRENTr,  W. L.  1989.  Cryptosporidium  spp. In Parasitic  infections 
in the compromised  host, P. D. Walzer,  and R. M. Genta (eds.). 
Marcel  Dekker,  New York, New York, p. 281-341. 
? 
1990.  Techniques and laboratory  maintenance  of Cryptos- 
poridium.  In Cryptosporidiosis  of man and animals,  J. P. Dubey, 
C. A. Speer,  and R. Fayer  (eds.). CRC  Press,  Boca Raton, Florida, 
p. 31-49. 
, AND T. B. HAYNES.  1984.  Complete  development  of Crypto- 
sporidium  in cell  culture.  Science  224:  603-605. 
.,  AND  N. C. REESE.  1986. A comparison  of endogenous  devel- 
opment  of three  isolates  of Cryptosporidium  in suckling  mice. Jour- 
nal of Protozoology  33: 98-108. 
, J. V. ERNST, W. S. BAILEY,  M. B. HEYMAN,  AND  W. M. 
WEINSTEIN.  1983.  Human cryptosporidiosis  in immunocompe- 
tent and immunodeficient  persons.  Studies  of an outbreak  and ex- 
perimental  transmission.  New England  Journal  of Medicine 308: 
1252-1257. 
EGGLESTON,  M. T., M. TILLEY,  AND S. J. UPTON.  1994.  Enhanced 
development of Cryptosporidium  in vitro by removal of oocyst 
toxins from infected  cell monolayers.  Proceedings  of the Helmin- 
thological  Society of Washington  61: 118-121. 
ERNEST,  J. A., B. L. BLAGBURN,  D. S. LINDSAY,  AND  W. L. CURRENT. 
1986.  Infection dynamics of Cryptosporidium  parvum  (Apicom- 
plexa:  Cyrptosporiidae)  in neonatal  mice (Mus musculus).  Journal 
of Parasitology  72: 796-798. 
FAYER,  R., AND  W. ELLIS.  1993. Glycoside  antibiotics  alone and com- 
bined with tetracyclines  for prophylaxis  of experimental  crypto- 
sporidiosis  in neonatal  BALB/c mice. Journal  of Parasitology  79: 
553-558. 
, T. NERAD,  W. RALL, D.  S. LINDSAY, AND  B.  L.  BLAGBURN. 
1991. Studies  on cryopreservation  of Cryptosporidium  parvum. 
Journal  of Parasitology  77: 357-361. 
, C. A. SPEER,  AND J. P. DUBEY. 1990.  General biology of Cryp- 
tosporidium.  In Cryptosporidiosis  of man  and animals,  J. P. Dubey, 
C. A. Speer,  and R. Fayer  (eds.). CRC Press,  Boca Raton, Florida, 
p. 1-30. 
FLANIGAN,  T. P., T. An, R. MARSHALL,  R. SOAVE,  M. AIKAWA,  AND  C. 
KAETZEL.  1991. Asexual  development  of Cryptosporidiumparvum 
within  a differentiated  human  enterocyte  cell line. Infection  and 
Immunity  59: 234-239. 
GUARINo,  A., M. I. SPAGNUOLO,  S. Russo, F. ALBANo,  S. GUANDAUNI, 
G. CAPANo,  S. CUCCHIARA,  P. VAIRANO,  R. LIGUORI,  A. CASOLA, 
AND A. RUBINO. 1995.  Etiology and risk factors of severe and 
protracted  diarrhea.  Journal  of Pediatric  Gastroenterology  and  Nu- 
trition 20: 173-178. 
Gurr,  J., C. PETERSON,  R. NELSON,  AND  J. LEECH.  1991.  Cryptospori- 
dium  parvum  in vitro cultivation in Madin-Darby  canine kidney 
cells. Journal  of Protozoology  38: 72S-73S. 
HARP,  J. A., AND  W. M. WHrMmIE.  1991.  Cryptosporidium  parvum 
in mice:  Inability  of lymphoid  cells or culture  supernatants  to trans- 
fer protection  from resistant  adults to susceptible  infants.  Journal 
of Parasitology  77: 170-172. 
ISAAcs,  D., G. H. HuNrr,  A. D. PmLUPS,  E. H. PRICE,  F. RAAFAT,  AND 
J. A. WALKER-SurrH.  1985.  Cryptosporidiosis  in immunocom- 
petent children.  Journal  of Clinical  Pathology  38: 76-81. 
LutM,  R., J. A. LANSER,  AND  P. J. O'DoNooHUE.  1988. Electrophoretic 
and  immunoblot  analysis  of Cryptosporidium  oocysts.  Immunology 
and Cell Biology 66: 369-376. 
This content downloaded by the authorized user from 192.168.52.63 on Wed, 28 Nov 2012 20:06:32 PM
All use subject to JSTOR Terms and Conditions762  THE  JOURNAL  OF  PARASITOLOGY,  VOL.  82, NO.  5, OCTOBER  1996 
MooN, H. W., D. B. WOODMANSEE,  J. A. HARP,  S. ABEL,  AND  B. L. P. 
UNGAR.  1988.  Lacteal  immunity to enteric cryptosporidiosis  in 
mice: Immune dams do not protect  their suckling  pups. Infection 
and Immunity  56: 649-653. 
MORGAN,  U. M., C. C. CONSTANTINE,  P. J. O'DONOGHUE,  B. P. MELONI, 
P. A. O'BRmEN,  AND  R. C. A. THOMPSON.  1995.  Molecular  char- 
acterisation  of Cryptosporidium  isolates from humans and other 
animals  using  RAPD (random  amplified  polymorphic  DNA) anal- 
ysis. American  Journal  of Tropical  Medicine  and Hygiene  52: 559- 
564. 
NOVAK,  S. M., AND  C. R. STERmING.  1991.  Susceptibility  dynamics  in 
neonatal BALB/c mice infected with Cryptosporidium  parvum. 
Journal  of Protozoology  38: 102S-104S. 
O'DoNoGoHUE,  P. J.  1995.  Cryptosporidium  and cryptosporidiosis  in 
man and animals. International  Journal  for Parasitology  25: 139- 
195. 
Pozio, E., M. A. G. MoRAL.ES,  F. M. BARBIm,  AND  G. LA  ROSA.  1992. 
Cryptosporidium:  Different  behaviour  in calves  of isolates  of human 
origin.  Transactions  of the Royal Society  of Tropical  Medicine  and 
Hygiene  86: 636-638. 
RASMUSSEN,  K. R., N. C. LARSEN,  AND  M. C. HEALEY.  1993.  Complete 
development Cryptosporidium  parvum in a human endometrial 
carcinoma  cell line. Infection  and Immunity  61: 1482-1485. 
ROHLMAN,  V. C., T. L. Kumus,  D. A. MOSmR,  D. L. CRAWFORD,  D. R. 
HAWKINS,  V. L. ABRnAMS,  AND  R. A. GREENInEu.  1993. Therapy 
with atovaquone  for Cryptosporidium  parvum  infection  in neonatal 
severe combined immunodeficiency  mice. Journal of Infectious 
Diseases 168: 258-260. 
SCAGLIA,  M., A. BRUBO,  G. CImcmNo,  C. ATZORI,  C. CEVINI,  AND  S. 
GATTI.  1991. Cryptosporidium  parvum  life cycle  in suckling  mice: 
A Nomarski interence-contrast  study of a human-derived  strain. 
Journal  of Protozoology  38: 118S-12  i1S. 
SHERWOOD,  D., K. W. ANGUs,  D. R. SNODORASS,  AND  S. TzIPoRI. 1982. 
Experimental  cryptosporidiosis  in laboratory  neonatal  mice. Infec- 
tion and Immunity  38: 471-475. 
SINsiu, E., M. BEDNARSKA,  AND  A.  ADAMCzEWSKA.  1992.  Biological 
characterisation  of Cryptosporidium  parvum  isolates  in suckling  and 
immunosuppressed  mice. Acta Parasitologica  37: 139-143. 
TzipoR, S. R., I. CAMPBE.LL,  AND  K. W. ANGUS. 1982. The therapeutic 
effects  of 16 antimicrobial  agents  on Cryptosporidium  in mice. Aus- 
tralian  Journal  of Experimental  Biology and Medical Science 60: 
187-190. 
UPTON,  S. J., M. TILLEY,  AND  D. B. BRILLHART.  1994a. Comparative 
development  of Cryptosporidium  parvum  (Apicomplexa)  in 11 con- 
tinuous host cell lines. FEMS  Microbiology  Letters  118: 233-236. 
, 
AND  .  1994b.  Comparative  development  of 
Cryptosporidium  parvum  in MDBK and HCT-8 cells under  select 
atmospheres.  Biomedical  Letters  49: 265-271. 
, 
AND  .  1995.  Effects of select medium  supple- 
ments  on in vitro  development  of Cryptosporidiumparvum  in HCT-8 
cells. Journal  of Clinical  Microbiology  33: 371-375. 
, M. V. NESTERENKO,  AND  D. B. BRILLHART.  1994.  A 
simple  and  reliable  method  of producing  in vitro  infections  of Cryp- 
tosporidium  parvum  (Apicomplexa).  FEMS Microbiology  Letters 
118: 45-50. 
WHmTEHEAD,  R. H., F. A. MACRAE,  D. J. B. ST. JOHN,  AND  J. MA.  1985. 
A colon cancer cell line (LIM1215) derived from a patient with 
inherited  nonpolyposis  colorectal  cancer.  Journal  of the National 
Cancer  Institute  74: 759-765. 
WooDs,  K. M.,  M. V. NEsTERENKo,  AND S. J. UPTON.  1995.  Devel- 
opment of a microtitre  ELISA  to quantify  development  of Cryp- 
tosporidium  parvum  in vitro. FEMS  Microbiology  Letters  128:  89- 
94. 
This content downloaded by the authorized user from 192.168.52.63 on Wed, 28 Nov 2012 20:06:32 PM
All use subject to JSTOR Terms and Conditions